Dados do Trabalho

Título

NEUROFILAMENT LIGHT CHAIN, β-AMYLOID 40, β-AMYLOID 42 AND TAU LEVELS IN PARKINSON’S AND CHAGAS DISEASE

Resumo

Introduction: The use of serum biomarkers as Neurofilament Light Chain[NfL], β-amyloid40[βA40], β-amyloid42[βA42] and Tau protein have been adressed for diagnosis risk and prognostic assessment of neurologic disorders, as marker of neurodegeneration. It is known that Chagas Disease (CD) is associated to stroke and cognitive impairment independently of cardiac disease severity. In this context, some of serum biomarkers may be altered in CD.
Objectives: To determine if serum NfL, βA40, βA42 and Tau levels are altered in patients with CD when compared to controls and Parkinson’s Disease (PD).
Methods: Cross-sectional study of adult (≥ 18 years) patients from a heart failure (HF) and movement disorders outpatient clinics. CD and control patients fulfilled Framingham criteria for HF; and had no history of stroke, recent thrombotic event or neurodegenerative diseases. CD was defined by a positive ELISA serologic test. The PD group fulfilled UK Bank criteria for PD; and had no dementia or parkinsonism of any other etiologies. NfL, βA40, βA42 and Tau were analyzed by single molecule array (SIMOA) technique. Multivariable analysis was performed using linear regression adjusted by age and sex.
Results: NfL was obtained from 22 patients with CD, 51 with PD and 24 controls. The median NfL was 7.73pg/ml in CD, 18.84 in PD and 8.81 in controls. NfL concentration adjusted for age/sex was 13.54pg/ml higher in PD compared to controls (p=0.006), but not different in CD group comparing to controls (p=0.24). βA40 was analyzed in 11 patients with CD, 50 with PD and 6 controls. Median βA40 was 0.73pg/ml in CD, 209.8 in PD and 3.01 in controls. Adjusted βA40 concentration was 207.07pg/ml higher in PD compared to controls (p<0.001) and there was no difference of βA40 levels in CD patients (p=0.77). Regarding βA42, were 14 samples of CD, 50 of PD and 5 of controls. The median was 0.41pg/ml in CD, 10.29 in PD and 0.75 in controls. Adjusted βA42 was 9.54pg/ml higher in PD comparing to control (p<0.001). CD had no effect on βA42 values (p=0.70). Finally, Tau presented median of 0.72pg/ml in CD, 2.17 in PD and 0.48 in controls, with 20 samples in CD, 50 in PD and 15 in control. In the adjusted analysis, CD and PD had no effect on protein Tau levels comparing to controls.
Conclusions: NfL, βA40 and βA42 were increased in PD when compared to controls. None of the serum biomarkers were different in CD compared to controls, suggesting that CD may affect cognition through different pathways.

Palavras Chave

Chagas Disease, Parkinson's Disease, Neurofilament Light Chain, β-amyloid 40, β-amyloid 42, Tau protein

Área

Neurologia Cognitiva E Do Envelhecimento